106 related articles for article (PubMed ID: 11323008)
1. Molecular modifications in factor VIII concentrates produced from different plasma pools.
Saenko E; Josic D; Stadler M; Sarafanov A; Lim Y; Shima M; Ananyeva N; Schwinn H
Thromb Res; 2001 Mar; 101(6):501-11. PubMed ID: 11323008
[TBL] [Abstract][Full Text] [Related]
2. Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.
Raut S; Di Giambattista M; Bevan SA; Hubbard AR; Barrowcliffe TW; Laub R
Thromb Haemost; 1998 Oct; 80(4):624-31. PubMed ID: 9798982
[TBL] [Abstract][Full Text] [Related]
3. A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates.
Chtourou S; Porte P; Nogré M; Bihoreau N; Cheesman E; Samor B; Sauger A; Raut S; Mazurier C
Vox Sang; 2007 May; 92(4):327-37. PubMed ID: 17456157
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
[TBL] [Abstract][Full Text] [Related]
5. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
6. Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII.
Grushin K; Miller J; Dalm D; Parker ET; Healey JF; Lollar P; Stoilova-McPhie S
Haemophilia; 2014 Sep; 20(5):723-31. PubMed ID: 24750465
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo evaluation of two factor VIII concentrates virally inactivated by solvent-detergent or by pasteurization.
Peerlinck K; Arnout J; Tamise M; Vanherle A; Fondu P; Vermylen J
Acta Clin Belg; 1991; 46(5):298-304. PubMed ID: 1661550
[TBL] [Abstract][Full Text] [Related]
8. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
9. Relationships between factor VIII:Ag and factor VIII in recombinant and plasma-derived factor VIII concentrates.
Lin Y; Yang X; Chevrier MC; Craven S; Barrowcliffe TW; Lemieux R; Ofosu FA
Haemophilia; 2004 Sep; 10(5):459-69. PubMed ID: 15357771
[TBL] [Abstract][Full Text] [Related]
10. Immunobiology of inhibitor development in hemophilia A.
Fijnvandraat K; Bril WS; Voorberg J
Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.
Laub R; Di Giambattista M; Fondu P; Brackmann HH; Lenk H; Saenko EL; Felch M; Scandella D
Thromb Haemost; 1999 Jan; 81(1):39-44. PubMed ID: 9974372
[TBL] [Abstract][Full Text] [Related]
12. The factor VIII/von Willebrand factor complex: basic and clinical issues.
Federici AB
Haematologica; 2003 Jun; 88(6):EREP02. PubMed ID: 12826528
[TBL] [Abstract][Full Text] [Related]
13. Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.
Walter JD; Werther RA; Polozova MS; Pohlman J; Healey JF; Meeks SL; Lollar P; Spiegel PC
J Biol Chem; 2013 Apr; 288(14):9905-9914. PubMed ID: 23417672
[TBL] [Abstract][Full Text] [Related]
14. A solvent I detergent treated, pasteurised and highly purified factor VIII concentrate.
Schwinn H; Stadler M; Josic D; Bal F; Gehringer W; Nur I; Schütz R
Arzneimittelforschung; 1994 Feb; 44(2):188-91. PubMed ID: 8147954
[TBL] [Abstract][Full Text] [Related]
15. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
16. Interaction of dicaproyl phosphatidylserine with recombinant factor VIII and its impact on immunogenicity.
Purohit VS; Balasubramanian SV
AAPS J; 2006 May; 8(2):E362-70. PubMed ID: 16796387
[TBL] [Abstract][Full Text] [Related]
17. Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display.
Mühle C; Schulz-Drost S; Khrenov AV; Saenko EL; Klinge J; Schneider H
Thromb Haemost; 2004 Mar; 91(3):619-25. PubMed ID: 14983240
[TBL] [Abstract][Full Text] [Related]
18. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
19. In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates.
Di Giambattista M; Branckaert T; Hougardy V; Kemball-Cook G; Laub R
Mol Immunol; 2007 Mar; 44(8):1903-13. PubMed ID: 17113150
[TBL] [Abstract][Full Text] [Related]
20. Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by computer-designed synthetic peptides.
Lebreton A; Moreau V; Lapalud P; Cayzac C; André S; Nguyen C; Schved JF; Lavigne G; Granier C
Br J Haematol; 2011 Nov; 155(4):487-97. PubMed ID: 21933172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
